Immatics N.V

Research Immatics N.V (IMTX) on Bullrun: market cap USD 1.31B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMTX
• ExchangeNASDAQ
• CountryGermany
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.31B
• Financial periodQ1 2026
• RevenueUSD 7.61M
• Net income-USD 57.81M
• Free cash flow-USD 188.90M

Valuation Snapshot

latest market cap is USD 1.31B.

About Immatics N.V

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial;

Frequently asked questions

What is Immatics N.V's market cap?

Immatics N.V's market capitalization is USD 1.31B.

What does Immatics N.V do?

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.